685535-77-7

Usage

Chemical structure

1H-Tetrazole, 1-[(2-bromo-5-chlorophenyl)methyl]-5-methylis a chemical compound with a complex structure consisting of a tetrazole ring and a phenylmethyl group with bromine and chlorine substitutions.

Stability

1H-Tetrazole, 1-[(2-bromo-5-chlorophenyl)methyl]-5-methyl- is relatively stable.

Potential applications

It has potential applications in the pharmaceutical and agrochemical industries.

Chemical modifications

The presence of the bromine and chlorine substituents makes it an interesting candidate for further chemical modifications and functionalization.

Hazards

Caution must be exercised when handling this chemical due to potential hazards associated with tetrazole compounds.

Further research

Further research and testing may be necessary to fully understand the properties and potential uses of this chemical.

Upstream product

• 66192-24-3 2-bromo-5-chlorobenzyl bromide 
• 4076-36-2 5-methyltetrazole 

Relevant academic research and scientific papers

[18F]PRIMATX, a New Positron Emission Tomography Tracer for Imaging of Autotaxin in Lung Tissue and Tumor-Bearing Mice

Autotaxin (ATX) is a secreted enzyme with tissue levels associated with tissue injury, which increase during wound healing and chronic fibrotic diseases. We selected [18F](R,E)-3-(4-chloro-2-((5-methyl-2H-tetrazol-2-yl)methyl)phenyl)-1-(4-((5-(2-fluoroethoxy)pyridin-2-yl)methyl)-2-methylpiperazin-1-yl)prop-2-en-1-one ([18F]PRIMATX, [18F]2), a tracer for positron emission tomography, to image ATX expression in vivo. It successfully differentiates expression levels in lung tissue samples from idiopathic pulmonary fibrosis patients, and allows the detection of ATX-expressing tumors in living mice, confirming its potential for development as a clinical imaging agent.

1-(4-BENZYL-PIPERAZIN-1-YL)-3-PHENYL-PROPENONE DERIVATIVES

A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is i